## **Enspryng (satralizumab-mwge) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	MBER:			
MALE FEMALE HEIG	GHT (IN/CM): WEIGH	HT (LB/KG): ALLERGI	IES:	
IF YOU ARE NOT THE PATIENT OR THE PRESCR FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM</u>	The state of the s	OSURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPR	RESENTATIVE (IF APPLICABLE):			
AUTHORIZED REPRESENTATIV	/E'S PHONE NUMBER:			
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page



## **Enspryng (satralizumab-mwge) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		NAME:
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Neuromyelitis optica spectrum disorder	(NMOSD)	100-10.
☐ Other diagnosis:ICD	-10	
	I: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.  Clinical Information:		
	quaporin-4 (AQP4) antibody? 🗆 Yes 🗆 🗈	No (please submit documentation)
•	ters with AND without assistance?	
Is the patient restricted to a wheelcha		.5 -110
·	ent with any IL-6 inhibitor?   Yes  No	
-	-	
	ent with alemtuzumab (Lemtrada®)?	res 🗆 No
Has the patient ever received total bo	•	
	marrow transplantation?   Yes   No	
Has the patient had at least one docu	mented NMOSD attack in the past 12 m	onths? 🗆 Yes 🗆 No
	le or recurrent episodes of longitudinally ⁄es □ No (please submit documentati	•
Does the patient have single or recurr	rent episodes of optic neuritis?   Yes	□ No (please submit documentation)
Are there any other comments, diagn physician feels is important to this re-	oses, symptoms, medications tried or fa view?	iled, and/or any other information the
Please note: Not all drugs/diagnosis and information is received.	re covered on all plans. This request may	be denied unless all required
	n provided is true and accurate to the be	•
	p or its designees may perform a routine curacy of the information reported on thi	•
Prescriber Signature or Electronic I.D.	Verification:	Date:
	companying this transmission contain confidential	
	reby notified that any disclosure, copying, distribut I have received this information in error, please no ese documents.	



## **Enspryng (satralizumab-mwge) Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811
St. Paul, MN 55164-0811

